International Journal of Infection

Published by: Kowsar

Comparing Hydroxychloroquine and Pyrimethamine With Sulfadoxine-Pyrimethamine to Treat Plasmodium berghei Infection in Mice

Mohammad Reza Vafaei 1 , Somayeh Jahani 2 , Hamed Kalani 1 and Nader Pestehchian 1 , *
Authors Information
1 Department of Parasitology and Mycology, Tropical Medicine Research Center, School of Medicine and Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • International Journal of Infection: April 2017, 4 (2); e41117
  • Published Online: August 31, 2016
  • Article Type: Research Article
  • Received: August 4, 2016
  • Accepted: August 13, 2016
  • DOI: 10.5812/iji.41117

To Cite: Vafaei M R, Jahani S, Kalani H, Pestehchian N. Comparing Hydroxychloroquine and Pyrimethamine With Sulfadoxine-Pyrimethamine to Treat Plasmodium berghei Infection in Mice, Int J Infect. 2017 ; 4(2):e41117. doi: 10.5812/iji.41117.

Abstract
Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Hansen DS. Inflammatory responses associated with the induction of cerebral malaria: lessons from experimental murine models. PLoS Pathog. 2012; 8(12): 1003045[DOI][PubMed]
  • 2. Athuman M, Kabanywanyi AM, Rohwer AC. Intermittent preventive antimalarial treatment for children with anaemia. Cochrane Database Syst Rev. 2015; 1: 10767[DOI][PubMed]
  • 3. World malaria report 2008. 2008;
  • 4. Global report on antimalarial drug efficacy and drug resistance 2000-2010. 2010;
  • 5. Krishna Ch V, Rao PV, Das GC, Kumar VS. Acute renal failure in falciparum malaria: clinical characteristics, demonstration of oxidative stress, and prognostication. Saudi J Kidney Dis Transpl. 2012; 23(2): 296-300[PubMed]
  • 6. Engwerda CR, Beattie L, Amante FH. The importance of the spleen in malaria. Trends Parasitol. 2005; 21(2): 75-80[DOI][PubMed]
  • 7. Basco LK. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. 2007;
  • 8. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization. 2008;
  • 9. Reyburn H. New WHO guidelines for the treatment of malaria. BMJ. 2010; 340: 2637[DOI][PubMed]
  • 10. Jambou R, El-Assaad F, Combes V, Grau GE. In vitro culture of Plasmodium berghei-ANKA maintains infectivity of mouse erythrocytes inducing cerebral malaria. Malaria J. 2011; 10(1): 1-5[DOI]
  • 11. Ajibade A, Adenowo T, Akintunde O, Fakunle P, Oyewo O, Ashamu E. Suppression of exploration and locomotion in adult Wistar rats following quinine administration. J Neurosci Behav Health. 2011; 3: 32-7
  • 12. Parapini S, Olliaro P, Navaratnam V, Taramelli D, Basilico N. Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays. Antimicrob Agents Chemother. 2015; 59(7): 4046-52[DOI]
  • 13. Andayi WA, Egan TJ, Gut J, Rosenthal PJ, Chibale K. Synthesis, Antiplasmodial Activity, and β-Hematin Inhibition of Hydroxypyridone-Chloroquine Hybrids. Acs Medicinal Chem Lett. 2013; 4(7): 642-6[DOI]
  • 14. Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015; 1342: 62-7[DOI][PubMed]
  • 15. Borlon C, Russell B, Sriprawat K, Suwanarusk R, Erhart A, Renia L. Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used for invasion and short term culture. Int J Parasitol. 2012; 42(2): 155-60[DOI]
  • 16. Ryley JF, Peters W. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970; 64(2): 209-22[PubMed]
  • 17. The Africa malaria report. 2003;
  • 18. Cibulskis RE, Aregawi M, Williams R, Otten M, Dye C. Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med. 2011; 8(12): 1001142[DOI][PubMed]
  • 19. Kumar A, Valecha N, Jain T, Dash AP. Burden of malaria in India: retrospective and prospective view. Am J Trop Med Hyg. 2007; 77(6 Suppl): 69-78[PubMed]
  • 20. Sharma VP. Battling the malaria iceberg with chloroquine in India. Malar J. 2007; 6: 105[DOI][PubMed]
  • 21. Bloland P, Kazembe P, Oloo A, Himonga B, Barat L, Ruebush T. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub‐Saharan Africa. Tropical Med Int Health. 1998; 3(7): 543-52[DOI]
  • 22. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999; 353(9168): 1965-7[PubMed]
  • 23. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999; 41(1-3): 301-8[PubMed]
  • 24. McIntosh HM, Jones KL. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. Cochrane Database Syst Rev. 2005; (4): 386[DOI][PubMed]
  • 25. Sezi C, Nevil C, Ochen K, Munafu C, Bekobita D. The response of Plasmodium falciparum to 4-aminoquinolines and pyrimethamine/sulfadoxine at six sites scattered throughout Uganda. Uganda Med J. 1991; 8: 33-46
  • 26. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001; 358(9279): 368-74[DOI]
  • 27. Falajiki Y, Akinola O, Abiodun O, Happi C, Sowunmi A, Gbotosho G. Amodiaquine-Ciprofloxacin: a potential combination therapy against drug resistant malaria. Parasitol. 2015; 142(6): 849-54[DOI]
  • 28. Visser BJ, Wieten RW, Kroon D, Nagel IM, Bélard S, van Vugt M. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malaria J. 2014; 13(1): 1-18[DOI]
  • 29. Gbotosho GO, Happi CT, Woranola O, Abiodun OO, Sowunmi A, Oduola AM. Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune. Parasitol Res. 2012; 110(2): 895-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments